<DOC>
	<DOCNO>NCT00649883</DOCNO>
	<brief_summary>This multicenter phase II trial evaluate safety immunogenicity two 0.25 mL 0.5 mL dos investigational influenza vaccine active control influenza vaccine healthy child age 6 &lt; 60 month .</brief_summary>
	<brief_title>Safety Immunogenicity Two 0.25 mL 0.5 mL Doses Two Different Influenza Vaccines Healthy Children Aged 6 &lt; 60 Months</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children 6 &lt; 60 month age , whose parents/legal guardian give write informed consent prior study entry . In good health determine : medical history , physical examination , clinical judgment investigator . Able comply study procedure Any serious disease , : cancer , autoimmune disease ( include rheumatoid arthritis ) , diabetes mellitus , chronic pulmonary disease , acute progressive hepatic renal disease , acute progressive neurological neuromuscular disease ; History anaphylaxis serious reaction follow administration vaccine , hypersensitivity egg , egg protein , chicken feather , influenza viral protein , vaccine component , chemically related substance , component potential packaging material ; Known suspect impairment/alteration immune function , include : immunosuppressive therapy , cancer chemotherapy , receipt immunostimulants within 60 day prior Visit 1 , receipt parenteral immunoglobulin know HIV infection HIVrelated disease ; Bleeding diathesis ; Surgery plan study period ; Receipt another investigational agent within 90 day Laboratoryconfirmed influenza disease within 6 month prior Visit 1 ; Ever receive two dos influenza vaccine study Receipt influenza vaccine within 6 month prior Visit 1 ; Experienced temperature 38.0Â°C within 3 day prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Influenza</keyword>
	<keyword>vaccine</keyword>
	<keyword>child</keyword>
</DOC>